Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors

Germ Cell Cancer Clinical Trial

Official title:

Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02303015
• Other study ID #: DaTeCa01
• Status: Completed
• Start date: August 2014
• Est. completion date: June 2023

Study information

• Verified date: November 2023
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to identify genetic variations in survivors of testicular cancer and connect these variations to differences in risks of late effects.

Description:

Identification of late-effects through questionnaires and linkage to national registries. DNA samples will be gathered through buccal swabs or saliva kits and analysed with whole exome-sequencing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 430
• Est. completion date: June 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Danish citizen
• Diagnosed with germ cell cancer from 1984 to 2007
• Treated initially at a Danish hospital
• Treated with standard treatment regimens.

Exclusion Criteria:

• Treated initially at a foreign hospital

Related Conditions & MeSH terms

• Germ Cell Cancer
• Neoplasms, Germ Cell and Embryonal

Locations

Country	Name	City	State
Denmark	Dept. of Oncology, Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renal toxicity (Identify genetic variations predicting renal toxicity)	Identify genetic variations predicting renal toxicity.	1 year